Literature DB >> 371651

The metabolism of [14C]-debrisoquine in man.

J R Idle, A Mahgoub, M M Angelo, L G Dring, R Lancaster, R L Smith.   

Abstract

1 The synthesis of [14C]-debrisoquine hydrochloride and 4-hydroxy-debrisoquine sulphate is described. 2 The metabolic fate and excretion profile in both urine and faeces of 14C-labelled debrisoquine was studied in five healthy human subjects. 3 Investigations showed that the drug is well-absorbed after a single oral dose of 32 mg and quantitatively eliminated from the body within three days. 4 4-Hydroxy-debrisoquine is the major metabolite of debrisoquine, although significant amounts of 5-,6-, 7- and 8-hydroxy-debrisoquine are also formed. 5 Electron-capture gas chromatography is a useful method for measuring debrisoquine and its five hydroxylated metabolites in urine at the pg level.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371651      PMCID: PMC1429493          DOI: 10.1111/j.1365-2125.1979.tb00930.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES WITH ANTIHYPERTENSIVE PROPERTIES.

Authors:  W WENNER
Journal:  J Med Chem       Date:  1965-01       Impact factor: 7.446

2.  The separation and identification of some sympathomimetic amines by paper partition chromatography.

Authors:  A WICKSTROM; B SALVESEN
Journal:  J Pharm Pharmacol       Date:  1952-09       Impact factor: 3.765

3.  Guanine in cancer.

Authors:  S GRAFF; M ENGELMAN; H B GILLESPIE; A M GRAFF
Journal:  Cancer Res       Date:  1951-05       Impact factor: 12.701

4.  Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.

Authors:  J G Allen; P B East; R J Francis; J L Haigh
Journal:  Drug Metab Dispos       Date:  1975 Sep-Oct       Impact factor: 3.922

5.  Oxidation of indan to indanol and indanone by the hepatic microsomal system.

Authors:  R E Billings; H R Sullivan; R E McMahon
Journal:  Biochemistry       Date:  1970-03-03       Impact factor: 3.162

6.  Routine identification of drugs of abuse in human urine. II. Development and application of the XAD-2 resin column method.

Authors:  S J Mulé; M L Bastos; D Jukofsky; E Saffer
Journal:  J Chromatogr       Date:  1971-12-23

7.  Hypotensive response to debrisoquine and hydroxylation phenotype.

Authors:  J R Idle; A Mahgoub; R Lancaster; R L Smith
Journal:  Life Sci       Date:  1978-03       Impact factor: 5.037

Review 8.  The influence of stereochemical factors on drug disposition.

Authors:  P Jenner; B Testa
Journal:  Drug Metab Rev       Date:  1973       Impact factor: 4.518

9.  Metabolism of debrisoquine sulphate in rat, dog and man.

Authors:  J G Allen; A N Brown; T R Marten
Journal:  Xenobiotica       Date:  1976-07       Impact factor: 1.908

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  17 in total

Review 1.  Development of analytical technology in pharmacogenetic research.

Authors:  Ann K Daly
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-25       Impact factor: 3.000

Review 2.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

3.  Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.

Authors:  P H Chapman; M D Rawlins; S Shuster; J R Idle; J C Ritchie; R L Smith
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Genetically determined oxidation capacity and the disposition of debrisoquine.

Authors:  T P Sloan; R Lancaster; R R Shah; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

Review 5.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

6.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

7.  Potential role of CYP2D6 in the central nervous system.

Authors:  Jie Cheng; Yueying Zhen; Sharon Miksys; Diren Beyoğlu; Kristopher W Krausz; Rachel F Tyndale; Aiming Yu; Jeffrey R Idle; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2013-04-25       Impact factor: 1.908

8.  Debrisoquine oxidation polymorphism in a Tasmanian population.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

10.  Acute renal failure following collective intoxication by Cortinarius orellanus.

Authors:  J Bouget; J Bousser; B Pats; M P Ramee; D Chevet; G Rifle; C P Giudicelli; R Thomas
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.